Chemomab Therapeutics Ltd (Chemomab), formerly Anchiano Therapeutics Ltd, is a clinical-stage biotechnology company dedicated to the discovery and development of novel treatments for inflammatory and fibrotic disorders with significant unmet medical needs. Chemomab developed CM-101, a monoclonal antibody designed to bind and inhibit CCL24 activity, based on the soluble protein CCL24's unique and crucial role in inducing fibrosis and inflammation. Numerous serious and potentially fatal fibrotic and inflammatory illnesses have shown possibilities for treatment with CM-101.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Chemomab's robust research and development infrastructure and talent enable the company to support early-stage discovery through clinical development. The company's R&D team is actively exploring the underlying fibro-inflammatory biology using a diverse range of in vitro and in vivo models, laying the groundwork for the creation of groundbreaking patient therapeutics. To further validate the unique role of CCL24 in fibrosis and demonstrate the therapeutic potential of CM-101 in reducing fibrosis and inflammation, Chemomab collaborates with esteemed researchers from renowned research institutions globally. These partnerships provide valuable insights that inform the development of CM-101 as a potentially transformative treatment option for patients. In FY2024, the company incurred research and development expense of US$11.2 million.